Northwest Biotherapeutics files new Form S-3 shelf before Oct 25, 2025

Northwest Biotherapeutics (NWBO) reported that it filed a new Form S-3 shelf registration on October 23, 2025 to replace its existing shelf.

Accepted by SEC EDGAR 10/24/2025 - 12:28 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Northwest Biotherapeutics (NWBO) reported that it filed a new Form S-3 shelf registration on October 23, 2025 to replace its existing shelf. Shelf registrations expire three years from effectiveness; the company’s current shelf became effective on October 25, 2022 and therefore expires on October 25, 2025. Filing the new shelf before expiration maintains an ongoing effective registration framework.

The company’s common stock trades on the OTCQB under the symbol NWBO.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NWBO disclose in this 8-K?

NWBO filed a new Form S-3 shelf registration on October 23, 2025 to replace its expiring shelf.

Why did Northwest Biotherapeutics (NWBO) file a new S-3 now?

Shelf registrations expire after three years; the existing shelf went effective on October 25, 2022 and expires on October 25, 2025.

What is the status of NWBO’s existing shelf registration?

It went effective on October 25, 2022 and expires on October 25, 2025.

What is the trading market and symbol for NWBO?

NWBO’s common stock trades on the OTCQB under the symbol NWBO.

What is the purpose stated for the new S-3 filing by NWBO?

To maintain an ongoing effective shelf registration by filing before the current shelf’s expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001072379 0001072379 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 23, 2025

Northwest Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		0-35737		94-3306718
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

4800 Montgomery Lane, Suite 800

Bethesda, Maryland 20814

(Address of Principal Executive Offices)

(240) 497-9024

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock, par value, $0.001 per share		NWBO		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01.  Other Events.

On October 23, 2025, the Company filed a new Form S-3 registration statement (“shelf registration”) to replace its existing shelf registration. Such registration statements expire 3 years from their effective date. The Company’s existing shelf registration went effective on October 25, 2022. As such, that registration statement expires on October 25, 2025. In order to maintain an ongoing effective shelf registration, it was necessary for the Company to file a new registration statement before the expiration of the existing one. Accordingly, the Company filed the new shelf registration on October 23, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NORTHWEST BIOTHERAPEUTICS, INC.
Date: October 24, 2025	By:	/s/ Linda Powers
	Name:	Linda Powers
	Title:	Chief Executive Officer and Chairman